Suchergebnisse
10
Alles
Adia Nutrition Advances Towards OTCQB Uplisting with Third-Party Audit and Provides Roadmap to Listing on Nasdaq Small Cap
05. Februar 2025 10:15 ET
|
ADIA Nutrition
WINTER PARK, Fla., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Adia Nutrition Inc. (OTC Pink: ADIA), an innovator nutritional products and medical treatments, has announced that through collaboration with...
Adia Nutrition Officially Enters $15.1 Billion Global Stem Cell Market with Domestic Treatments by Successful Opening of First Florida Location
03. Februar 2025 08:30 ET
|
ADIA Nutrition
WINTER PARK, Fla., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Adia Nutrition Inc. (OTC Pink: ADIA), through its medical division Adia Med, is strategically positioning itself to capture a significant share...
Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT
27. Januar 2025 08:30 ET
|
Fortress Biotech, Inc.
Study is the first randomized, controlled trial examining a vaccine’s effectiveness in controlling CMV in recipients of HSCT from vaccinated donors Encouraging pilot study results demonstrated the...
Telix’s TLX66 in Phase II Academic Study of Pediatric Leukemia
16. August 2021 19:55 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and LONDON , Aug. 17, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the London-based Great Ormond Street Hospital...
Bellicum Pharmaceuticals Presents Encouraging Preclinical Data for GoCAR-NK Cell Program at Society for Immunotherapy of Cancer Annual Meeting
08. November 2019 07:00 ET
|
Bellicum Pharmaceuticals, Inc.
iMC activation enhances innate NK cell cytotoxicity against tumor cell lines in vitro MC activity enhances the efficacy of CAR-NK cells against hematological and solid tumor models MC signaling...
Bellicum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
30. August 2019 16:08 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 30, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Pharmaceuticals to Participate in Three Healthcare Investor Conferences during September
28. August 2019 16:05 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 28, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Pharmaceuticals Announces Aggregate Gross Proceeds of $69.6 Million from $139.6 Million Public Offering and Private Placement
21. August 2019 16:05 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 21, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Pharmaceuticals Announces Proposed $53.0 Million Public Offering of Preferred Stock and Warrants with Concurrent Private Placement
15. August 2019 17:37 ET
|
Bellicum Pharmaceuticals, Inc.
HOUSTON, Aug. 15, 2019 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers and orphan inherited blood...
Bellicum Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Operational Update
05. August 2019 16:15 ET
|
Bellicum Pharmaceuticals, Inc.
Interim safety and activity data for BPX-601 presented at American Society of Clinical Oncology (ASCO) Annual Meeting Rivo-celTM achieved primary endpoint in BP-004 European registrational trial ...